Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ying-Nan P Chen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature|May 26, 2006
Validating cancer drug targetsJohn D Benson, Ying-Nan P Chen, Susan A Cornell-Kennon, et al.
Cancer Cell|January 30, 2004
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complexMaina Lepourcelet, Ying-Nan P Chen, Dennis S France, et al.
Organic Letters|January 30, 2009
Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRbKarl J Hale, Soraya Manaviazar, Linos Lazarides, et al.
Cell Chemical Biology|September 5, 2020
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein DegradationJing Zhang, Liqiang Fu, Bin Shen, et al.
Cancer Research|June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy EfficacyAlvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Journal of Medicinal Chemistry|June 28, 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase InhibitorJorge Garcia Fortanet, Christine Hiu-Tung Chen, Ying-Nan P Chen, et al.
Nature|July 1, 2016
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesYing-Nan P Chen, Matthew J LaMarche, Ho Man Chan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature|May 26, 2006
Validating cancer drug targetsJohn D Benson, Ying-Nan P Chen, Susan A Cornell-Kennon, et al.
Cancer Cell|January 30, 2004
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complexMaina Lepourcelet, Ying-Nan P Chen, Dennis S France, et al.
Organic Letters|January 30, 2009
Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRbKarl J Hale, Soraya Manaviazar, Linos Lazarides, et al.
Cell Chemical Biology|September 5, 2020
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein DegradationJing Zhang, Liqiang Fu, Bin Shen, et al.
Cancer Research|June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy EfficacyAlvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Journal of Medicinal Chemistry|June 28, 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase InhibitorJorge Garcia Fortanet, Christine Hiu-Tung Chen, Ying-Nan P Chen, et al.
Nature|July 1, 2016
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesYing-Nan P Chen, Matthew J LaMarche, Ho Man Chan, et al.
Pageof 1